ArticleAnnals of translational medicine2021

Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.

Xinglu Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.